Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab

Immune checkpoint inhibitors (ICIs) have changed the landscape of how we treat metastatic non-small cell lung cancer (NSCLC). However, many patients do not respond to ICI-based treatment and are at risk for severe immune -related adverse events (irAE). Better predictive and prognostic tools are needed. Platelets have been shown to be implicated in carcinogenesis and tumor progression by secretion of growth factors and cytokines. In prior studies, our group has demonstrated decreasing mean platelet volume during early treatment with ICIs was associated with improved overall survival and increased rate for irAE.